Fact Based List:

Top Ten U.S. Drugs (by sales) Losing Patent Exclusivity in 2021

Submitted by gmccalister on Tue, 05/25/2021 - 10:03


  1. Lucentis (Genentech/Roche) 2020 $1.6 Billion in sales
  2. Bystolic (AbbVie/Allergan) 2020 $600 Million in sales
  3. Vascepa (Amarin) 2020 $598 Million in sales
  4. Nothera (Lundbeck) 2020 $416 Million in sales
  5. Narcan (Emergent Biosolutions) 2020 $311 Million in sales
  6. Brovana (Sunovion) 2020 $275 Million in sales
  7. Sutent (Pfizer) 2020 $223 Million in sales
  8. Saphris (AbbVie/Allergan) 2020 $217 Million in sales
  9. Amitiza (Mallinckrodt) 2020 $180 Million in sales
  10. Feraheme (Amag Pharma) 2020 $150 Million in sales


Source: JDSupra, April 29, 2021
Source URL: https://www.jdsupra.com/legalnews/top-drugs-losing-patent-ex...


Printer-friendly versionPrinter-friendly versionSend to friendSend to friendmore...  

List Ratings:   
0
No votes yet
Your rating: None

Lists You Might Also Be Interested In



    Login or register to post comments